Immunome (IMNM) said Monday that the first patient has been dosed in its phase 1 trial evaluating IM-3050, an investigational therapy for advanced solid tumors.
The trial, an open-label, multicenter dose-escalation and expansion study, is meant to determine the safety, tolerability, dosimetry, pharmacokinetics and preliminary anti-tumor activity of IM-3050 in participants with fibroblast activation protein-expressing advanced solid tumors, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.